Latest News and Press Releases

To NASDAQ OMX Copenhagen A/S Announcement no. 20-12 / Copenhagen, November 6, 2012 The Board of Directors has decided to advance the release of Topotarget’s interim report for Q3 2012 from...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 19-12 / København, 2. november 2012 Hermed indkaldes til ekstraordinær generalforsamling i Topotarget A/S: Mandag den 26. november 2012 kl....

To NASDAQ OMX Copenhagen A/S Announcement No. 19-12 / Copenhagen, November 2, 2012 Notice is hereby given that an Extraordinary General Meeting of Topotarget A/S will be held on: Monday,...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 18-12 / København, 15. oktober 2012 Den 15. oktober 2012 tildelte Europa-Kommissionen Topotarget A/S Orphan Drug-status for belinostat, selskabets...

To NASDAQ OMX Copenhagen A/S Announcement no. 18-12 / Copenhagen, October 15, 2012 On October 15, 2012, the European Commission granted Topotarget A/S an Orphan Drug Designation for belinostat,...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 17-12 / København, 3. oktober 2012 De foreløbige resultater fra det første stadie af fase II-delen af det kliniske fase I/II studie med belinostat i...

To NASDAQ OMX Copenhagen A/S Announcement no. 17-12 / Copenhagen, October 3, 2012 Initial results from the first stage of the phase II part of the phase I/II clinical trial of belinostat in...

To NASDAQ OMX Copenhagen A/S Announcement no. 16-12 / Copenhagen, Denmark September 21, 2012 Topotarget A/S today announced that the primary endpoint has been met for the belinostat pivotal...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 16-12 / København, Danmark 21. september 2012 Topotarget A/S har i dag meddelt, at det primære effektmål er opfyldt i det pivotale studie med...

To NASDAQ OMX Copenhagen A/S Announcement No. 15-12 / Copenhagen, September 17, 2012 Copenhagen, Denmark – September 17, 2012 – Today Topotarget A/S (NASDAQ OMX: TOPO) announced that clinical...